Glory has completed several phase I, II, and III clinical trials in several hundred human patients with highly encouraging results.
The most inspiring feature reported during the above trials is that CHML appears to be non-toxic to human bodies. Additionally, immune function actually increased an average of 20 - 30% after therapy.
With worldwide patents approved, CHML is currently under evaluation in the United States for cancer therapy. Although we highly anticipate CHML's approval, it is likely that this will require further testing, and unfortunately, more time.
Time is a luxury that may have significant limitations for terminally diagnosed Individuals. For these individuals, we have been granted the opportunity to provide CHML therapy at our modern, state-off-the-art facility, without delay.
To date, several hundred patients have been treated with CHML. Recent independent evaluations by leading scientists and organizations have called CHML one of the most exciting new anti-cancer agents available.
The majority of individuals receiving CHML treatment have been late stage patients. Usually, these patients have exhausted a broad range of conventional and/or alternative cancer treatments. Those with a history of significant conventional intervention are normally the most difficult to treat. However, even in these cases, CHML has been successful.
Most importantly, CHML treatment has been accompanied by virtually none of the side effects commonly associated with cancer chemotherapy.
CHML may be administered by: IV drip, local injection, or by a sophisticated new technology which allows area-specific, concentrated drug delivery. Using DSA (Digital Subtraction Angiography), CHML is delivered directly to a site of major concern by Arterial Infusion.
At high concentrations, CHML was able to attain significant penetration into tumor networks and attain marked destruction of the tumor's feeding system in less than 30 minutes. Immediate, significant vessel disruption was effected in a number of different malignant tumors.
Clinical studies demonstrate that patients receiving a lower rate of arterial infusion and IV drip, at 8 hours per day and 10-25 day per cycle, obtainined longer terms for cancer relapse.